H. Kantarjian

Fludarabine: a new agent with major activity against chronic lymphocytic leukemia

MJ Keating, H. Kantarjian, Moshe Talpaz et al. · Blood · 1989 · 456 citations · Full text

Medicine, Oncology, Pharmacology +9

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up

Richard A. Larson, Andreas Hochhaus, Timothy P. Hughes et al. · Leukemia · 2012 · 440 citations

Medicine, Hematology, Oncology +11

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib

Andreas Hochhaus, Michele Baccarani, Michael W. Deininger et al. · Leukemia · 2008 · 354 citations

Medicine, Hematology, Oncology +13

Mylotarg? (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation

Francis J. Giles, H. Kantarjian, Steve Kornblau et al. · Cancer · 2001 · 281 citations

Medicine, Hematology, Oncology +15

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis

Alessandro M. Vannucchi, H. Kantarjian, Jean‐Jacques Kiladjian et al. · Haematologica · 2015 · 253 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13